Suppr超能文献

评价复方谷氨酰胺肠溶胶囊治疗肠易激综合征的有效性和安全性:系统评价和 Meta 分析方案。

To assess the effective and safety of compound glutamine entersoluble capsules in irritable bowel syndrome: A protocol for systematic review and meta-analysis.

机构信息

Department of Gastroenterology, Sichuan Second Chinese Medicine Hospital.

College of Computer Science, Chengdu University, Chengdu, Sichuan.

出版信息

Medicine (Baltimore). 2021 Mar 12;100(10):e25098. doi: 10.1097/MD.0000000000025098.

Abstract

BACKGROUND

Irritable bowel syndrome (IBS) is one the common medical condition of functional GI disorder (FGD) characterized by bowel-related symptoms without other organic gastrointestinal (GI) disease. Compound Glutamine Entersoluble Capsules(CGEC),a compound preparation in which each capsule contains 120 mg L-glutamine, 50 mg ginseng, 50 mg licorice, 50 mg Atractylodes macrocephala and 50 mg Poria cocos, have been reported the efficacy of CGEC for patients with IBS in improving the clinical symptoms and quality of patients' life. However, there is no a systematic review related to CGEC for IBS to this day. In this study, we will systematically evaluate the effectiveness and safety of CGEC in the treatment of IBS-D with a meta-analysis method, so as to provide a solid evidence for clinical practice.

METHODS

In this study, a literature search was performed by using the Chinese and English databases, which include PubMed, Embase, MEDLINE, Cochrane Library Central Register of Controlled Trials, China National Knowledge Infrastructure (CNKI) database, Wanfang Data Knowledge Service Platform, the VIP information resource integration service platform (cqvip), China Biology Medicine Disc (Sino Med),and the Chinese Clinical Trial Registry (ChiCTR), to find the related literature of CGEC in the treatment of IBS published from the inception date of each predefined database upto January 2021. The evaluation of the risk of bias for eligible studies will be performed by two investigators. Data synthesis will be performed by RevMan 5.4 software. Heterogeneity between studies can be assessed by a heterogeneity X2 test. The degree of heterogeneity among multiple included studies can be measured by I2. The stability of systematic review or meta-analysis outcomes will be evaluated by Sensitivity analysis. Reporting bias will be evaluated by funnel plot. Finally, The Grading of Recommendations Assessment, Development and Evaluation (GRADE) will be used to assess the quality of evidence obtained.

RESULTS

The results of this study will be published in a peer-reviewed journal.

CONCLUSION

Whether it is the effectiveness and safety of CGEC in the treatment of IBS will be judged in the result of this systematic review.

摘要

背景

肠易激综合征(IBS)是一种常见的功能性胃肠道疾病(FGD),其特征为与肠道相关的症状,而无其他器质性胃肠道(GI)疾病。复方谷氨酰胺肠溶胶囊(CGEC)是一种复方制剂,每粒胶囊含有 120mg L-谷氨酰胺、50mg 人参、50mg 甘草、50mg 白术和 50mg 茯苓。已有报道称 CGEC 可改善 IBS 患者的临床症状和生活质量。然而,迄今为止,尚无关于 CGEC 治疗 IBS 的系统评价。在本研究中,我们将采用荟萃分析方法系统评价 CGEC 治疗 IBS-D 的有效性和安全性,为临床实践提供坚实的证据。

方法

本研究通过中文和英文数据库(包括 PubMed、Embase、MEDLINE、Cochrane 图书馆对照试验中心注册库、中国知网数据库、万方数据知识服务平台、维普信息资源整合服务平台(cqvip)、中国生物医学文献数据库(Sino Med)和中国临床试验注册中心(ChiCTR))检索了从每个预定义数据库的创建日期到 2021 年 1 月发表的关于 CGEC 治疗 IBS 的相关文献。两名研究者将对合格研究的偏倚风险进行评估。数据综合将采用 RevMan 5.4 软件进行。通过异质性 X2 检验评估研究间的异质性。采用 I2 测量多个纳入研究间的异质性程度。通过敏感性分析评估系统评价或荟萃分析结果的稳定性。通过漏斗图评估报告偏倚。最后,将采用推荐评估、制定与评价(GRADE)等级评估获得证据的质量。

结果

本研究的结果将发表在同行评议的期刊上。

结论

本系统评价的结果将判断 CGEC 治疗 IBS 的有效性和安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/202d/7969248/96914fee4766/medi-100-e25098-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验